Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms

被引:0
|
作者
Pang, Chaoyu [1 ]
Li, Yongzheng [1 ]
Shi, Ming [1 ]
Fan, Zhiyao [1 ]
Gao, Xin [1 ]
Meng, Yufan [1 ]
Liu, Shujie [1 ]
Gao, Changhao [1 ]
Su, Peng [2 ]
Wang, Xiao [2 ]
Zhan, Hanxiang [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Gen Surg, Div Pancreat Surg, Jinan, Shandong, Peoples R China
[2] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan, Shandong, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
GEP-NEN G3; neuroendocrine neoplasm; CXCR4; clinicopathological features; prognosis; CHEMOKINE RECEPTORS; TUMOR-GROWTH; SURVIVAL; CELL; AXIS;
D O I
10.3389/fendo.2024.1281622
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: CXC chemokine receptor 4 (CXCR4) is associated with the progression and metastasis of numerous malignant tumors. However, its relationship with Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3 (GEP-NENs G3) is unclear. The aim of this study was to characterize the expression of CXCR4 in GEP-NENS and to explore the clinical and prognostic value of CXCR4. Methods: This study retrospectively collected clinical and pathological data from patients with GEP-NENs who receiving surgery in Qilu Hospital of Shandong University from January 2013 to April 2021, and obtained the overall survival of the patients based on follow-up. Immunohistochemistry (IHC) was performed on pathological paraffin sections to observe CXCR4 staining. Groups were made according to pathological findings. Kaplan-Meier (K-M) curve was used to evaluate prognosis. SPSS 26.0 was used for statistical analysis. Results: 100 GEP-NENs G3 patients were enrolled in this study. There was a significant difference in primary sites (P=0.002), Ki-67 index (P<0.001), and Carcinoembryonic Antigen (CEA) elevation (P=0.008) between neuroendocrine tumor (NET) G3 and neuroendocrine carcinoma (NEC). CXCR4 was highly expressed only in tumors, low or no expressed in adjacent tissues (P<0.001). The expression level of CXCR4 in NEC was significantly higher than that in NET G3 (P=0.038). The K-M curves showed that there was no significant difference in overall survival between patients with high CXCR4 expression and patients with low CXCR4 expression, either in GEP-NEN G3 or NEC (P=0.920, P=0.842. respectively). Conclusion: Differential expression of CXCR4 was found between tumor and adjacent tissues and between NET G3 and NEC. Our results demonstrated that CXCR4 can be served as a new IHC diagnostic indicator in the diagnosis and differential diagnosis of GEP-NENs G3. Further studies with multi-center, large sample size and longer follow-up are needed to confirm the correlation between CXCR4 expression level and prognosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
    Rebekka Mai
    Daniel Kaemmerer
    Tina Träger
    Elisa Neubauer
    Jörg Sänger
    Richard P. Baum
    Stefan Schulz
    Amelie Lupp
    [J]. Scientific Reports, 9
  • [2] Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
    Kaemmerer, Daniel
    Traeger, Tina
    Hoffmeister, Maike
    Sipos, Bence
    Hommann, Merten
    Saenger, Joerg
    Schulz, Stefan
    Lupp, Amelie
    [J]. ONCOTARGET, 2015, 6 (29) : 27566 - 27579
  • [3] Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
    Mai, Rebekka
    Kaemmerer, Daniel
    Traeger, Tina
    Neubauer, Elisa
    Saenger, Joerg
    Baum, Richard P.
    Schulz, Stefan
    Lupp, Amelie
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [4] Comparative evaluation of somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms of different origin
    Mai, R.
    Kaemmerer, D.
    Traeger, T.
    Neubauer, E.
    Saenger, J.
    Schulz, S.
    Lupp, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 48 - 48
  • [5] Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms
    Kaemmerer, Daniel
    Reimann, Christiane
    Specht, Elisa
    Wirtz, Ralph M.
    Sayeg, Manal
    Baum, Richard P.
    Schulz, Stefan
    Lupp, Amelie
    [J]. ONCOTARGET, 2015, 6 (05) : 3346 - 3358
  • [6] CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
    Sanchis-Pascual, David
    Del Olmo-Garcia, Maria Isabel
    Prado-Wohlwend, Stefan
    Zac-Romero, Carlos
    Huerta, Angel Segura
    Hernandez-Gil, Javier
    Marti-Bonmati, Luis
    Merino-Torres, Juan Francisco
    [J]. CANCERS, 2024, 16 (10)
  • [7] Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin
    Mai, R.
    Kaemmerer, D.
    Saenger, J.
    Neubauer, E.
    Schulz, S.
    Lupp, A.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 219 - 219
  • [8] Somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) of different origin and malignancy
    Mai, R.
    Kaemmerer, D.
    Saenger, J.
    Neubauer, E.
    Schulz, S.
    Lupp, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 282 - 282
  • [9] Differential Somatostatin and CXCR4 Chemokine Receptor Expression in Primary Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) and Their Metastases
    Kaemmerer, D.
    Traeger, T.
    Saenger, J.
    Schulz, S.
    Lupp, A.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 3 - 3
  • [10] Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms
    David S. Klimstra
    [J]. Endocrine, 2016, 53 : 4 - 6